China MNCs Shift Focus To Off-Patent Generics
This article was originally published in PharmAsia News
With the arrival of the “patent cliff” this year, many multinational pharma companies in China have ramped up their efforts in the generics market.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.